+ mononuclear cells regenerating vast amounts of infarct-damaged myocardium in rodents, as described by Orlic et al 1 in Nature in 2001, captured the imagination of the field and even the public. However, these results were refuted by 2 reports in Nature 3 years later in which bone marrow-derived c-Kit + cells were shown to be incapable of becoming cardiac myocytes under an array of conditions.
T he description of bone marrow-derived c-Kit
+ mononuclear cells regenerating vast amounts of infarct-damaged myocardium in rodents, as described by Orlic et al 1 in Nature in 2001, captured the imagination of the field and even the public. However, these results were refuted by 2 reports in Nature 3 years later in which bone marrow-derived c-Kit + cells were shown to be incapable of becoming cardiac myocytes under an array of conditions. 2, 3 The scenario with bone marrow c-Kit + cells is much a primer for the greater field of cardiac regeneration and what has transpired during the past 15 years. Indeed, the subsequent assertion that the heart has an endogenous pool of stem cells, c-Kit + or otherwise, that can regenerate the heart by making new cardiomyocytes after injury or with aging 4, 5 remains contentious and is the primary source of current ongoing controversy in the field. 6 Some of the underlying controversy surrounding putative c-Kit + progenitor cells likely results from an array of experimental and theoretical considerations that are discussed in detail by Keith and Bolli 7 in a recent review on this subject. Moreover, despite the presence of c-Kit + cells and other proposed putative stem cells within the adult mammalian heart, this organ nonetheless remains poorly regenerative and not capable of producing >1% cardiomyocyte renewal per year, which primarily result from cardiomyocyte proliferation. There are also basic tenets of stem cell biology that the proposed c-Kit + cardiac progenitor cell hypothesis breaks (will be discussed below). These and other lines of evidence collectively suggest an emerging consensus hypothesis that the adult heart lacks a physiologically meaningful, cardiomyocyte-producing stem cell.
Evidence That Existing Cardiomyocytes Proliferate to Create New Myocardium
The early neonatal mouse heart was recently shown to fully regenerate after either a resection surgical procedure or a myocardial infarction (MI) due to the proliferation of myocytes surrounding the area of injury. 8 Moreover, when adults from lower vertebrates, such as zebrafish or newt, are subjected to a cardiac apical resection procedure, they show complete regeneration with new myocardium primarily due to the proliferation of existing cardiomyocytes. [9] [10] [11] [12] [13] In fact, studies in zebrafish even showed that adult heart regeneration was not due to the action of a progenitor cells, c-Kit + or otherwise, indicating an evolutionary ground state for cardiac repair that does not require unrelated progenitor cells. 13 Moreover, regeneration of the zebrafish heart was shown to be due to the activity of a subset of endogenous cardiomyocytes that contain a somewhat specialized transcriptional program that affords proliferative potential.
because the fully differentiated state has yet to occur, whereas in zebrafish there is less need for highly differentiated cardiomyocytes throughout the heart, given the reduced hemodynamic pressures of this species. 13 This general paradigm could extend to the adult mammalian heart, whereby small numbers of endogenous cardiomyocytes retain some sort of molecular signature of a less differentiated state to account for a low level of new myocyte production that has been unanimously documented. 13 Recent studies have also identified molecular pathways that can be exploited to augment the inherent ability of some endogenous cardiomyocytes to re-enter the cell cycle. 14, 15 The field is attempting to dissect the molecular circuitry and genes that underlie cell cycle control and the extent to which cardiomyocyte differentiation progresses or even how to coax a dedifferentiated state of the cardiomyocyte in the hopes of attaining more substantial proliferation. 13, 16, 17 Again, zebrafish and other lower organisms do not use c-Kit + or other types of progenitor cells in creating new cardiomyocytes in the heart; hence, there is lack of evolutionary conservation for a proposed mechanism involving stem cells making new myocytes.
The adult mouse or human heart seems to have the ability to generate as much as 1% to 2% new cardiomyocytes each year. 6, 17 Studies dating back ≈20 years had already made a convincing technical argument that cardiomyocytes within the adult mouse heart can only undergo limited cell cycle activity of ≈1% per year. 18 The most conclusive of these studies was from Soonpaa and Field, 19 in which they measured DNA synthesis in the mouse heart with [
3 H]-thymidine in a transgenic model expressing β-galactosidase (also referred to as, LacZ) in only cardiomyocyte nuclei for unequivocal scoring. More recently, in vivo cellular labeling in the mouse with [ 15 N]-thymidine multi-isotope imaging mass spectrometry showed a similar rate of 1% cardiomyocyte renewal per year, but from existing cardiomyocytes. 20 Finally, 2 studies in the human heart were conducted based on the postmortem analysis of hearts for [
14 C]-isotope labeling in individuals that were alive during the nuclear testing era when atmospheric levels of this carbon isotope were exceedingly high, as well as afterward when atmospheric levels dropped to only trace levels. 21, 22 In both a first study published in 2009 in Science and a subsequent study published in 2015 in Cell, the estimated rate of cardiomyocyte DNA synthesis was placed at 0.5% to 1.5% per year in adult humans. 21, 22 The conclusion that cardiomyocytes within the adult mammalian heart have a limited capacity for renewal of ≈1% per year from existing myocytes would seem to be solid, as the data span at least 3 different approaches and some 20 years' time and emanate from independent laboratories lacking known association or co-publications. However, this potential conclusion apposed previous and ongoing claims from the laboratories that had reported cardiomyocyte renewal rates an order of magnitude higher and that this renewal was because of the activity of progenitor cells. 4 The argument put forth by Anversa et al 23 in a recent review is based on assumptions of ongoing rates of cardiomyocyte apoptosis in the heart at baseline. They suggest that the heart loses significant and progressively more numbers of cardiomyocytes each year because of ongoing apoptosis, so there must be a much higher level of new myocyte formation than 1% per year to maintain cellular homeostasis at baseline. 23 However, it is just as possible that rates of ongoing apoptosis in the human heart were previously overestimated by 5-to 10-fold, which would then bring the balance back into synchronization of ≈1%. Indeed, Saraste et al 24 estimated rates of ongoing cardiomyocyte apoptosis in control adult atrial and ventricular tissue of ≈1.0% to 3.5% each year, which is more similar to the accepted rates of yearly cardiomyocyte renewal that was discussed above. Hence, the assertion that the adult mammalian heart has a limited endogenous capacity to generate new cardiomyocyte is likely consistent with the comparably low rates of cardiomyocyte loss each year.
Relevance of Putative Adult Cardiac Progenitor Cell Sources
We have attempted to focus our discussion on the natural ability of the heart to regenerate and produce new cardiomyocytes, either at baseline, with aging, or after an injury event. This focus on endogenous repair seems important in defining a starting point in which we can all agree, so that we can attempt to tackle more controversial areas while also holding to basic tenets of biology. For example, it is well established that the failing heart gradually loses cardiomyocytes over time and that this phenomenon underlies a significant aspect of heart failure progression toward death. It is also observed clinically that areas of injured myocardium, whether scarred or not, do not appreciably resolve in patients. 25 Hence, the adult heart is arguably incapable of meaningful self-renewal, but the yearly 1% cardiomyocyte proliferation rate discussed above could be physiologically meaningful when summated over several decades. Finally, this 1% cardiomyocyte renewal rate that is observed each year in the heart seems to be primarily because of the activity of existing cardiomyocytes, not the activity of an adult cardiac progenitor cell.
Some past studies using progenitor cells collected from bone marrow, the heart itself, or other selected tissues have reported remarkable levels of new cardiomyocyte formation within the heart when injected, which also restored cardiac function after MI injury. 4, 5 Indeed, as discussed in the opening paragraph, Orlic et al 1 claimed that bone marrow c-Kit + Lin − -fractionated cells could regenerate 68% of an infarcted region of the rodent heart with new healthy myocardium by the direct recommitment of these cells into cardiomyocytes and vascular cells. Two years later, Beltrami et al 26 from the same laboratory claimed that c-Kit + cells isolated from the heart itself, expanded ex vivo and injected back into the infarction injured rodent heart, could directly regenerate 70% of this region with new contractile tissue. Although these results are remarkable, they remain at odds with data from other laboratories and the known biology of c-Kit + cells in general and the basic tenets of stem cell biology that were discussed above and will be expanded on in a subsection at the end of this review. 6, 27, 28 It is also important to note that the approach by Beltrami et al, 26 in which they isolated and exogenously expanded c-Kit + cells for injection into the heart, does not necessarily reflect the underlying natural endogenous repair capacity of the heart so that injections of such cells in a transplantation experiment might still provide some other benefit to the heart, such as a paracrine effect. 7, 29 If unique progenitor-like cells are someday reproducibly identified from the heart, 29 or properly re-engineered, 30 such cells could be therapeutically meaningful in generating new cardiomyocytes when injected in vivo. The reprogramming of cardiac fibroblasts with cardiac-inducing transcription factors was clearly shown to create new cardiomyocytes, 31 although endogenous fibroblasts are not cardiomyocyte progenitor cells. Another tenet to consider is that if cells were successfully re-engineered to make bona fide new cardiomyocytes in vivo at an appreciable level, they would likely cause arrhythmia, as shown recently with human embryonic stem cells programmed to become new immature cardiomyocytes and injected into the nonhuman primate heart. 32 Such arrhythmias would develop because inductions of low-resistance pathways in the cardiac conduction syncytium promotes current re-entry leading to premature excitation. Hence, one could argue that perhaps the reason arrhythmias were not described in past animal studies or human clinical trials with c-Kit + -derived cells, whether from bone marrow or expanded from the heart itself, is because new contracting cardiomyocytes were never generated. Otherwise, it should have induced arrhythmias.
These caveats aside, an emerging consensus from animal studies and even human studies with cellular transplantation experiments is that the field has yet to identify, in an interlaboratory reproducible manner, a putative progenitor cell population that can transdifferentiate into beating cardiomyocytes once injected in vivo. 29 Hence, past studies that reported the ability of injected c-Kit + progenitors to directly generate new cardiomyocytes in restoring heart tissue and function in experimental injury models need to be re-examined with exchanging of samples and personnel between independent laboratories. Indeed, such an exchange was indirectly accomplished when Tang et al 33 and Hong et al 34 published 2 recent papers, whereby they isolated then injected cardiac c-Kit + cells into the injured rodent heart, showing that essentially none of these cells become cardiac myocytes and that most simply perished and were no longer detectable within a few weeks. Hence, even without a discussion of the most recent Kit allele lineage tracing results from the past 2 years, as will be presented below, a consensus is already emerging that holds that c-Kit + cells are not physiologically relevant cardiomyocyte-producing progenitors, and when they are injected into the heart they simply die. However, injection of c-Kit + cells into the injured rodent myocardium nonetheless augmented cardiac function likely through a paracrine mechanism of action. 33, 34 Kit Allele Lineage Tracing to Examine Endogenous Cardiac Regeneration Cre allele faithfully recapitulated endogenous c-Kit protein expression throughout all known regions in the mouse (bone marrow, intestine, testis, skeletal muscle, skin, and lung), including endogenous c-Kit + mononuclear cells within the heart, both low and high expressing. 35 Remarkably, this lineage tracing strategy, at 4 weeks of age, showed only 0.027% cardiomyocyte labeling although endothelial cells were abundantly labeled. 35 Importantly, the Kit Cre allele is expressed constitutively throughout all development and adulthood; hence, a rate of 0.027% cardiomyocyte labeling at 4 weeks of age indicated that c-Kit-expressing progenitor cells are not appreciably part of the primary heart field during embryogenesis, 35 in contrast to previous reports suggesting otherwise. 7, 36 These results also indicate that embryonic and adult cardiomyocytes do not express the Kit allele in its properly configured state. However, transgenic approaches that utilize fragments of the Kit promoter to drive expression will likely not reflect true endogenous expression, even producing ectopic expression in cardiomyocytes, as Kit allele promoter fragments (even large ones) are unreliable in vivo. 28 To isolate the formation of new cardiomyocytes in the adult mouse heart after injury, van Berlo et al 35 also targeted the Kit allele with the tamoxifen-regulated MerCreMer cDNA (Kit
MerCreMer

). Lineage tracing with the Kit
MerCreMer allele and the R-eGFP reporter allele identified extremely low rates of eGFP + -traced cardiomyocytes in the adult heart with various labeling times up through 6 months of age. 35 MI injury to the adult heart showed rates of new eGFP + -traced cardiomyocytes of only 0.016% and only 0.007% after isoproterenol infusioninduced injury, indicating that endogenous c-Kit + cells were not generating significant new cardiomyocytes in vivo after injury. 35 Importantly, these results were recently confirmed in a blinded manner by another independent laboratory. 37 More specifically, Wallner et al 37 used the exact same mice as van Berlo et al 35 and reported a nearly identical low rate of Kitdependent lineage-traced cardiomyocytes at baseline in the adult heart, as well as no appreciable increase after isoproterenol injury.
Although the results of van Berlo et al 35 showed a low rate of new cardiomyocyte generation in the heart from Kit lineage-traced cells, more careful investigation showed that ≈85% of these labeled cardiomyocytes were simply because of fusion of c-Kit-traced immune cells with cardiomyocytes.
Recall that all immune cells in the Kit
Cre lineage tracing mice will be eGFP + , as they are descended from c-Kit + hematopoietic progenitors. Hence, the true rate of c-Kit + cells having cardiomyocyte progenitor capacity is even much lower, ≈0.005% throughout development and 0.002% after injury to the heart. 35 This consideration notwithstanding, the results of van Berlo et al 35 still demonstrate that c-Kit + cells have some definable rate of generating de novo cardiomyocytes in the heart, although it is highly unlikely to be physiologically meaningful. In contrast, c-Kit + lineage-traced cells did generate abundant CD31 + endothelial cells in the heart, indicating that these cells are endothelial progenitors that are likely to be important for vascular repair in the heart and of potential medicinal value. At the minimum, these results of widespread CD31 + cell production from a putative hemangioblast c-Kit + progenitor cell demonstrates the validity of the Kit allele targeting and that the heterozygosity of this locus does not disrupt the basic biology of c-Kit-expressing cells. The genetic lineage tracing data of van Berlo et al was immediately questioned, 38 but was quickly supported in the literature by another independent study from Sultana et al. 39 In this later study, Sultana et al 39 ). These targeted lines each mirrored endogenous c-Kit expression in the mouse in known regions, such as heart, lung, liver, intestine, stomach, melanocytes, spleen, and umbilical cord. 39 Using these genetic tools, it was confirmed that c-Kit + cells were indeed endothelial progenitors but that they did not generate appreciable cardiomyocytes. 39 More specifically, Kit allele-traced cells did not express the myocardial-specific marker cTnT (cardiac troponin T) after birth or during development of the heart (<0.04% at embryonic day 13.5 to postnatal day 60; <0.007% after postnatal day 90). These results again support the conclusion that c-Kit + cells are not myocardial progenitor cells, in contrast to previous suggestions. 7, 36 On MI injury, Sultana et al 39 showed that the Kit allele lineage-traced cells still maintained their endothelial cell propensity, with <0.002% of myocardial cells identified. These observations support van Berlo et al 35 and again suggest that c-Kit + cells lack significant cardiomyocyte progenitor cell activity. Moreover, using another independent approach that would bypass concerns of cellular fusion, Sultana et al 39 used mice containing a Kit MerCreMer allele that were crossed with mice containing a cardiac-specific reporter knock-in allele (cTnT nlacZ-/H2B-GFP ). This elegant approach further confirmed that c-Kit + cells rarely generate de novo cardiomyocytes in the heart (≈0.005% of total c-Kit + cells and ≈0.002% of total myocardial cells in the heart). 39 As even further evidence, a third independent research group also recently described the generation of Kit alleledependent lineage tracing mice. 40 Liu et al 40 targeted the Kit allele with the CreERT2 cDNA for tamoxifen-inducible Cre recombinase activity, which they also used in conjunction with a Rosa26 red fluorescent protein (RFP) reporter allele (Kit
CreERT2
; Rosa26 RFP ). Here, the authors examined Kit lineage cells in the heart at 48 hours after tamoxifen treatment, revealing a low number of RFP + cardiomyocytes (0.035%). Importantly, these RFP + cardiomyocytes were unlikely to have been generated by differentiation of c-Kit + progenitors, given such a short time window. 40 Indeed, Liu et al 40 suggested that RFP + cardiomyocytes detected in the heart at baseline with injury were from cardiomyocytes that expressed the Kit CreERT2 allele itself rather than by differentiation of c-Kit + progenitors. This means that the Kit allele itself can be rarely and randomly activated in cardiomyocytes, further downplaying the cardiomyogenic potential of c-Kit + cells in the heart. They also showed that MI injury did not promote an increase in c-Kit + lineage-traced cardiomyocytes (0.035% at baseline versus 0.034% after MI). 40 However, van Berlo et al 35 generated data suggesting that c-Kit + cells can produce low levels of cardiomyocytes in vivo and that it is not simply aberrant activation of Kit Cre in rare cardiomyocytes. van Berlo et al 35 generated Kit null embryos and showed that they lacked this low rate of lineage-traced cardiomyocytes in the developing heart. Importantly, full deletion of the Kit gene (both alleles) essentially eliminates the progenitor activity of c-Kit + cells, 35 but it would have no effect on spontaneously activating the Kit Cre allele in a cardiomyocyte, meaning that the loss of the low level of lineage-traced cardiomyocytes in the embryonic heart with Kit deletion proves that c-Kit + cells have this low level activity of de novo cardiomyocyte creation.
Finally, a fourth group also recently reported Kit alleledependent lineage tracing in the heart. Klein et al 41 generated an independent version of Kit CreERT2 knock-in mice, which were constructed with 2 independent ATG-containing first exons. Using these mice, Hatzistergos et al 42, 43 traced the progeny of c-Kit + cells in the early embryonic and postnatal heart. They used Kit CreERT2 in conjunction with Wnt1::Flpe and dual-recombinase responsive indicators (RC::Fela and RC::Frepe) 44, 45 and detected cardiac neural crest-derived cKit-traced cells in the early mouse embryo, although quantification was not performed so that the potential significance of this finding is unclear. 43 However, Hatzistergos et al 42, 43 reported that the lineage-traced cardiomyocytes in the early embryonic and postnatal c-Kit + cells were significantly lower than expected, as well as lacking in labeled endothelial cells. It should be noted that the Kit CreERT2 allele used in this study has 2 engineered ATG start sites that seem to disrupt true Kit expression, given that these mice show no labeling of bone marrowderived c-Kit + cells, other than mast cells. 44, 46 Nevertheless, all these studies with Kit allele-dependent lineage tracing do not exclude the ability of neonatal-derived c-Kit + cells manipulated in culture to express select cardiomyocyte-specific genes.
47, 48 The results discussed in this section simply indicate that endogenous c-Kit + cells lack full cardiomyogenic potential in vivo, whether during embryonic, postnatal development or in the adult heart under any conditions.
Concerns With Kit Allele-Based Lineage Tracing
The primary criticism of the lineage tracing approaches discussed above is that they produce a single Kit null allele based on the knock-in procedure itself (partial loss of function), meaning heterozygosity in c-Kit expression and a possible alteration in the activity of c-Kit-expressing progenitor cells. We discussed this issue at length in a recent editorial and why this is unlikely to be a significant overall concern, 49 but will briefly discuss the evidence again here, as this issue continues to resurface. 50 First, single-allele Kit Cre mice (heterozygous) showed the same number of c-Kit + mononuclear cells within the heart and in bone marrow as wild-type controls, indicating no reduction in c-Kit + cellular content because of heterozygosity. 49 Moreover, isolation of these Kit allele heterozygous January 20, 2017
cells from the adult heart revealed the same potential as wildtype cells to upregulate aspects of cardiac gene expression under dexamethasone culture conditions, such as induction of Gata4 and troponin T expression (reference (35) [Extended Data Figure 9 ] and data not shown). Also, the recombination efficiency of the Kit Cre allele and the lineage tracing approach is ≈80%, generating the concern that the unlabeled, possibly lower expressing c-Kit + cells, might preferentially contribute to a specialized pool of cells that more readily generates cardiomyocytes. However, van Berlo et al 35 have shown that recombined and nonrecombined c-Kit + progenitors (antibody sorted) from the heart equally induced Gata4 and cTnT expression under dexamethasone treatment, suggesting that the unlabeled c-Kit + cells are not more cardiomyogenic. 35 Finally, Kit
Cre heterozygous mice still showed abundant endothelial cell production in the heart; hence, they maintain their true progenitor-like functionality in generating this cell type, despite the loss of 1 Kit allele.
35,39
Basic Tenets of Stem Cell Biology From Known Regenerative Tissues
The proposition that cardiac c-Kit + cells function as endogenous cardiomyocyte-producing stem cells breaks with the biology of how stem cells function as defined in known regenerative tissues. For example, adult mammalian skeletal muscle is highly regenerative and within this tissue stem cells comprise as much as 5% of the total nuclei. More importantly, these stem cells are interspersed evenly throughout the tissue so as to respond to both small local areas of injury and also to generate widespread and temporally homogenous regeneration after larger injury events. Skeletal muscle stem cells (also referred to as satellite cells) are easily isolated and made to differentiate into myotubes in a highly reproducible manner across all laboratories that work in the field. Moreover, injecting skeletal muscle satellite cells into different tissues, such as the heart, directly generates only skeletal muscle cell containing grafts. 51 Indeed, even c-Kit + progenitor cells isolated from bone marrow, where such cells function as true hematopoietic progenitors, only generate immune cells when injected into the heart. 2, 3 Finally, tissues that regenerate because of the activity of an endogenous stem cell show an evolutionary conservation in this mechanism at least down through zebrafish. These basic tenets of stem cell biology are all broken by the concept that the heart contains a c-Kit + progenitor cell predetermined to generate new cardiomyocytes. First, c-Kit + mononuclear cells in adult mouse heart are exceedingly rare with total levels estimated at 1 to 5 cells per histological section of the entire heart. 35 This is clearly too sparse of a cellular concentration to coordinate meaningful renewal. Second, c-Kit + cells are not used by zebrafish for heart regeneration, but instead existing cardiomyocytes are the underlying mechanism of regeneration. Third, the field cannot reproducibly isolate a definable c-Kit + cell population from the adult heart that differentiates into beating cardiomyocytes in culture or when injected back into the heart. 33, 34, 47, 48 Finally, as stated earlier, if abundant new cardiomyocytes were acutely generated after an injury from a stem cell source of some sort it would be arrhythmic and potentially lethal. Hence, the entire concept of a predestined cardiomyocyte-producing c-Kit + stem cell being present within the heart breaks the known biological principles of stem cell biology in regenerative tissues.
Conclusion and Future Directions
In this review, we supported one view of a long-standing area of controversy in cardiac regeneration because we think that the emerging body of data in the literature points only in this direction. More than this, basic tenets of biology support a broader conclusion that the adult mammalian heart is not an inherently regenerative organ when left to its own devices; hence, it likely lacks a true physiological stem cell pool as defined in other regenerative tissues. Second, the rate of cardiomyocyte renewal activity in the adult heart of 1% per year is astonishingly low, below the level that would be expected if there was a true endogenous stem cell present in the heart that was predetermined to make new cardiomyocytes. Not to mention that previous studies showed that such renewal was primarily because of proliferation of existing cardiomyocytes, which is a conserved mechanism in zebrafish. Third, genetic lineage tracing strategies in the mouse from multiple unlinked and independent laboratories do not support the concept that endogenous c-Kit + cells generate cardiomyocytes at physiologically meaningful levels, with estimates spanning from 1 in 3500 cells to well over 1 in 50 000 or even nonexistent.
In addition to a lack of a c-Kit + cardiomyocyte-producing stem cell, other genetic strategies have similarly downplayed the likelihood that a non-c-Kit + -expressing stem cell might exist in the heart contributing to meaningful renewal or repair (eg, side population cells, 52 Sca-1-expressing cells, 53 and cells derived from the adult epicardium 54 ). Mesenchymal stromal cells were also previously proposed as having cardiomyogenic potential, but these cells are essentially fibroblast-like stromal cells from the bone marrow that recent studies have shown possess no ability to generate cardiomyocytes. 7 Finally, even studies with ex vivo expanded progenitor cells, or primary isolated bone marrow mononuclear cells, which were injected into the heart and claimed to generate abundant new cardiomyocytes, have been refuted because of lack of reproducibility and the inability to define these presumed stem cells consistently between laboratories.
Although we highlighted an emerging consensus hypothesis here that the heart lacks a cardiomyocyte-producing stem cell as classically defined, this new state of affairs does not refute in any way the greater concept of cellular therapy as a potential treatment for human heart disease. Indeed, cardiomyocytes derived from induced pluripotent stem cells, from embryonic stem cells, 32 and even from the transcriptional reprogramming of other cell types 31 have emerged as cellular approaches for attempting to regenerate the heart. In this context, perhaps reprogramming c-Kit + cells would be more efficient than attempting to reprogram fibroblasts with cardiogenic transcription factors as c-Kit + cells already have a low predilection for inducing cardiomyocytes in vivo or at least induction of cardiac differentiation-specific genes. 35 Lastly, cellular therapies have other potential benefits that require more investigation, such as the paracrine hypothesis, which proposes that selected secreted factors produced by the injected cells within the damaged area of the heart can impart better cardiac function through multiple cellular rejuvenating mechanisms. 7, 33, 34 Thus, considering the data collected in animal models, whereby injected progenitor cells from various sources all uniformly seem to benefit the heart through nonengraftment-dependent mechanisms, more research is needed to understand the basic biology of these observations. 
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